{"analyses":[{"ciLowerLimit":"11.05","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"27.37","estimateComment":"Wald with Continuity Correction","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Difference in Response Rate","paramValue":"19.21","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2"},{"groupId":"OG001","value":"41.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"452"},{"groupId":"OG001","value":"227"}],"units":"Participants"}],"description":"ORR (confirmation not required) is defined as the proportion of participants with an objective response, either CR or PR, with the use of RECIST v1.1, as determined by the investigator in the ITT-WT population.","groups":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","id":"OG000","title":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurs first during induction treatment phase. Participants will receive best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed is also permitted. Participants who were consented prior to approval of protocol Version 5 will be given the option to cross over to receive atezolizumab as monotherapy until disease progression.","id":"OG001","title":"Arm B (Nab-Paclitaxel+Carboplatin)"}],"paramType":"NUMBER","populationDescription":"The ITT- WT population was defined as the ITT population excluding participants with an activating EGFR mutation or ALK translocation","reportingStatus":"POSTED","timeFrame":"Up to approximately 41 months after first subject enrolled","title":"Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}